An updated coronary risk profile. A statement for health professionals.
about
Economic Benefits of Treating High-Risk Hypertension with Angiotensin II Receptor Antagonists (Blockers)Correlates of fitness for duty in hazardous materials firefighters.Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health studyPredictive accuracy of the Framingham coronary risk score in British men: prospective cohort studyThe 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of riskThe 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of riskThe 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of riskThe 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of riskGPs' decisions on drug treatment for patients with high cholesterol values: a think-aloud studyWhat is the best strategy for reducing deaths from heart disease?Long-term vitamin E supplementation fails to reduce lipid peroxidation in people at cardiovascular risk: analysis of underlying factors.Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factorsA computer decision aid for medical prevention: a pilot qualitative study of the Personalized Estimate of Risks (EsPeR) systemThe role of guidelines and the patient's life-style in GPs' management of hypercholesterolaemiaRational Prescribing in Primary Care (RaPP-trial). A randomised trial of a tailored intervention to improve prescribing of antihypertensive and cholesterol-lowering drugs in general practice [ISRCTN48751230]Combining information from multiple data sources to create multivariable risk models: illustration and preliminary assessment of a new methodImpact of provision of cardiovascular disease risk estimates to healthcare professionals and patients: a systematic reviewDevelopment of Antiatherosclerotic Drugs on the basis of Natural Products Using Cell Model ApproachClinical prediction rules in practice: review of clinical guidelines and survey of GPsCoronary heart disease prevention: insights from modelling incremental cost effectivenessUndertreatment and overtreatment with statins: the Oslo Health Study 2000-2001Evaluating national guidelines for prevention of cardiovascular disease in primary careBarriers to a trial of atherosclerosis prevention in systemic lupus erythematosusThe cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling studyThe use of cardiovascular risk factor information in practice databases: making the best of patient dataAn appraisal of aspirin therapy in diabetesCost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of TanzaniaThe effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trialAngiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trialEthnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE--Southall And Brent REvisited)Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality predictionUsing additional information on working hours to predict coronary heart disease: a cohort studyDistribution of 10-year and lifetime predicted risk for cardiovascular disease in the Indian Sentinel Surveillance Study population (cross-sectional survey results)Sex-Specific Prediction Models for Sleep Apnea From the Hispanic Community Health Study/Study of LatinosDrug-induced blood pressure increase - recommendations for assessment in clinical and non-clinical studies.Clinical problem solving based on the 1999 Canadian recommendations for the management of hypertension.1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of HypertensionCerebral cortical hyperactivation in response to mental stress in patients with coronary artery disease.Excess pressure integral predicts cardiovascular events independent of other risk factors in the conduit artery functional evaluation substudy of Anglo-Scandinavian Cardiac Outcomes TrialImmunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.
P2860
Q22305821-EB6EF9D1-66B6-47F2-9B05-88D6F9BBF1CBQ24169544-D1FF76E1-97CB-462C-ADB4-98DCEEEB9092Q24629648-7987F259-9B41-491B-9A35-38E5BB2A2527Q24630111-FE1ACFE0-1A84-47EC-A66A-BC7115077E0DQ24645401-F9B4E786-8B82-4378-AABC-EC18D0B0E2F6Q24651499-7DFAA3ED-2D0A-4BCA-BE6E-00BDE7F771F4Q24652860-79BBA43F-4EDA-4248-AE56-797CC59A7B43Q24658014-A77A54A0-1DB6-4F73-A2AD-726BB1DFF641Q24792131-3FB17818-7959-4F36-8EBF-8D396E3CB6EAQ24792163-3F556D37-0253-47AB-8091-7F8FAB474917Q24794281-EF6BB6ED-9433-4BAD-B828-A6BB64DF7E62Q24796318-204CF78A-AE42-4EFE-A375-C1B07A2CECCAQ24806011-183C54E0-ABBB-4936-9863-43AF63850459Q24806073-ADE3E895-5080-40AF-9F49-C440C9AAD564Q24806535-50655304-FF42-4CCE-B0B3-2EA112751D4AQ24811660-1A4D74B4-E344-45B8-B6B9-BB9067ECBC3AQ26778836-C38B863F-20A4-45EE-A9CF-A41EBB9034BDQ26782745-26BAADC1-F69F-465A-A5DC-649A20428CA9Q27002373-74DE8CA7-CB51-4A10-9F18-051E2AB8748EQ28166294-66C41960-BB88-4EF5-BED5-545611328053Q28168028-350AACD9-B616-490F-92F9-A7C560920D38Q28191895-B056DFD9-E5AF-48F9-95C0-3C2B2FD01A09Q28192401-9EE8AB06-6745-4B6B-BBE4-73536F1BDC05Q28199830-01F80292-DD0A-47BF-A6A1-2BA9FD09A1A3Q28199922-D739FB65-0030-4366-90B4-75BEBD611998Q28210871-64F5D20B-FA2A-4AC3-A825-3F1E3F8E0891Q28219296-B88CFCC3-1F3E-483C-8E39-48FDFB57001BQ28475969-A0190DFE-E7B1-448C-9B57-74B80891830BQ28484460-B2736E92-BC36-4F88-9EEB-19E9F7302C8EQ28602638-87231F2C-05BD-40F6-B71A-A0C948E26547Q28731264-C1145BE0-0D75-4892-8CDB-7FF23EB5E074Q28741690-D3DC0D25-B2B0-4B45-A514-6E6E26DD4513Q28744014-4BAF43FB-FB8C-446E-AC43-2FC0746D02B6Q30355032-9786D04E-AB6F-4042-8927-046999B06162Q30395099-FC89936D-5D3D-4045-8D41-9CF708FC25BBQ30499043-5BCB9AB6-C8FC-41F3-A593-10A08635037FQ30499045-95CE09BC-95B8-4EB5-9AE1-D7986F01F24EQ30530638-E19F457C-B8E0-4D42-987E-C500BFE8C37FQ30581310-66683E49-CE4D-4D8E-836E-134C6B6A433BQ30593046-6B440041-9528-4E07-A6AB-67B4439586C4
P2860
An updated coronary risk profile. A statement for health professionals.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
An updated coronary risk profile. A statement for health professionals.
@en
An updated coronary risk profile. A statement for health professionals.
@nl
type
label
An updated coronary risk profile. A statement for health professionals.
@en
An updated coronary risk profile. A statement for health professionals.
@nl
prefLabel
An updated coronary risk profile. A statement for health professionals.
@en
An updated coronary risk profile. A statement for health professionals.
@nl
P2093
P356
P1433
P1476
An updated coronary risk profile. A statement for health professionals.
@en
P2093
P304
P356
10.1161/01.CIR.83.1.356
P407
P577
1991-01-01T00:00:00Z